Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
Information source: Johns Hopkins University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Idiopathic Pulmonary Fibrosis (IPF)
Intervention: Thalidomide (Drug)
Phase: Phase 2
Sponsored by: Johns Hopkins University
Official(s) and/or principal investigator(s):
Maureen R Horton, M.D., Principal Investigator, Affiliation: Johns Hopkins School of Medicine
The goal of this study is to determine whether thalidomide can stop the progression of
fibrosis in IPF.
The primary objective of this study is to determine the safety, feasibility and efficacy of
400 mg of thalidomide administered daily for one year in patients with idiopathic pulmonary
fibrosis (IPF) who have failed or are not candidates for treatment with corticosteroids
and/or cytotoxic drugs.
The study population will consist of patients with biopsy-proven moderate to severe IPF who
have failed or are not candidates for standard therapy with corticosteroids and/or cytotoxic
Official title: Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: To determine the safety, feasibility and efficacy of 400 mg of thalidomide administered daily for one year in patients with IPF who have failed or are not candidates for treatment with corticosteroids and/or cytotoxic drug.
Secondary outcome: The efficacy of thalidomide in preventing progressive pulmonary fibrosis and clinical deterioration measured objectively with changes in PFTs and radiographs as well as with dyspnea scales and quality of life measures.
This is an unmasked Phase II, safety and efficacy trial of subjects with biopsy-proven IPF
who have failed or are not candidates for standard therapy with corticosteroids and/or
cytotoxic drugs. The study doctors are interested in studying the effects of the oral drug
Thalomid(R) on IPF. Thalomid(R) (thalidomide) is an approved medication for Hansen's disease
(leprosy). It is know to have anti-inflammatory effects and effects on fibrosis. It is
hoped that Thalomid(R) may prevent progression of IPF.
Thalidomide is investigational for this use, which means that it has not been approved by the
U. S. Food and Drug Administration (FDA) for the treatment of IPF.
The age range for this study is 50-80 years, inclusive. There are 6 visits over the 12 month
period. These visits include physical exams, pregnancy tests (if applicable), several
symptom scales and questionnaires about your pulmonary fibrosis, pulmonary function testing,
x-rays,peripheral nerve testing, and blood tests including arterial blood gas measurements.
You will be given the medication in capsule form every 28 days for a year. There is a set
schedule for increasing the doses of the thalidomide every 2 weeks until it reaches the 400
mg. dose that is being studies. A stool softener is also provided for each participant.
All subjects must read, sign and follow a manual of precautions prepared by Celgene, the
manufacturer of Thalomid(R), before enrolling in this study. This manual, containing the
S. T.E. P.S.(R) precautions, will be given to all participants.
This study is being conducted at the Johns Hopkins Medical Institutions located in Baltimore,
Minimum age: 50 Years.
Maximum age: 80 Years.
- Clinical history consistent with IPF for greater than or equal to 3 months duration
and less than 5 years.
- Documented IPF with UIP on histologic examination of surgical lung biopsy confirmed by
study physician (RT).
- High resolution CT (HRCT) of chest consistent with IPF (bibasilar reticular
abnormalities with minimal ground glass opacities) as determined by study physician
- Failure to have >/= 10% increase in FVC on prior adequate treatment with
corticosteroids and/or cytotoxic drugs, or intolerance to these drugs precluding use.
- FVC >/= 40% and = 90% predicted at screening.
- DLCo >/= 25% predicted at screening
- Oxygen saturation >/= 88% on room air or = 2L oxygen at screening.
- Age 50-80 inclusive
- Ability to understand and sign informed written consent form and comply with study
- Known etiology of ILD (e. g. sarcoid, hypersensitivity pneumonitis, BOOP etc.)
- Clinically significant toxic or environmental exposure to respiratory irritants (e. g.
drugs, asbestosis, radiation etc.)
- Diagnosis of collagen vascular disease.
- Obstruction on PFTs, defined as FEV1/FVC < 0. 6.
- Active infection
- End stage coronary artery disease, congestive heart failure or cor pulmonale
- History of significant peripheral vascular disease
- History of peripheral neuropathy
- History of clinically significant obstructive sleep apnea
- History of poorly controlled diabetes
- Pregnant or lactating women
- Abnormal laboratories as defined as: WBC < 2300/mm3, HCT < 30% or >55%, PLT <
100k/mm3. creatinine >1. 5, AST or ALT > 3x normal, total bilirubin > 1. 5.
- Current enrollment in another protocol for IPF
- Prednisone use >15 mg a day in 4 weeks prior to starting trial.
- Cytotoxic drugs (cyclophosphamide, azathioprine, colchicines, cyclosporine,
interferon-gamma) 6 weeks prior to screening.
- Patients requiring chronic narcotic analgesic.
- Patients unable to give informed consent.
- Patients unable to comply with the requirements for the trial.
- Patients with known allergy/intolerance to thalidomide;
- Patients with a predicted life expectance less than 6 months.
Locations and Contacts
Johns Hopkins School of Medicine, Baltimore, Maryland 21287, United States
Johns Hopkins Pulmonary & Critical Care Medicine website
Pulmonary Fibrosis Foundation
Starting date: October 2003
Ending date: July 2007
Last updated: October 30, 2007